Egg oral immunotherapy in children (SEICAP I): Daily or weekly desensitization pattern
| Autor: | L. Echeverria, Cristina Blasco, Catalina Gómez, Blanca Vilá, S. Nevot, Elena Alonso Lebrero, Lidia Zapatero Remón, María Flora Martín-Muñoz, Juan Miguel García Martinez, Candelaria Muñoz Román, Mónica Piquer Gibert, A.M. Plaza, Rosario Madero Jarabo, María Teresa Belver, Cristina Martorell-Calatayud, Antonio Martorell-Aragonés, Victoria Fuentes Aparicio |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Oral immunotherapy medicine.medical_treatment Immunology Administration Oral Immunoglobulins law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Double-Blind Method law Internal medicine medicine Immunology and Allergy Humans 030212 general & internal medicine Dosing Child Egg Hypersensitivity Asthma Desensitization (medicine) Skin Tests business.industry Egg Proteins Allergens medicine.disease Threshold dose Treatment Outcome 030228 respiratory system Desensitization Immunologic Egg allergy Pediatrics Perinatology and Child Health Female business Egg white Follow-Up Studies |
| Zdroj: | Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 30(1) |
| ISSN: | 1399-3038 |
| Popis: | BACKGROUND Studies are required before incorporating egg oral immunotherapy (OIT) into clinical practice. The Spanish Society of Pediatric Allergy, Asthma and Clinical Immunology (SEICAP) conducted a multicenter, randomized controlled study assessing the effectiveness and safety of the OIT using pasteurized egg white (PEW) in egg-allergic children. METHODS One hundred and one egg-allergic children (6-9 years) were randomized for 1 year: 25 to an egg-free-diet (CG) and 76 to OIT (target dose 3.3 g PEW proteins), PI (30% weekly plus 5% daily increments) or PII (only 30% weekly increments) buildup patterns. Egg skin prick test, sIgE and sIgG4 serum levels, PEW double-blind placebo-controlled food challenge (DBPCFC), and dosing adverse reactions (DARs) were evaluated in all patients from inclusion (T0) until completing 1 year of follow-up (T12). At T12, egg-allergic control patients could start OIT. The effectiveness and safety of OIT and the effect of the buildup pattern were analyzed. RESULTS At T12, 4/25 (16.0%) CG patients passed the PEW DBPCFC vs 64/76 (84.2%) OIT that reached total desensitization (P = 0.000); 12 egg-allergic control patients started OIT. Finally, 72/88 (81.81%) patients reached total desensitization, 96.15% PI vs 75.80% on PII (P = 0.01). Induction period (121.12 ± 91.43, median 98.00 days) was longer in patients on PII buildup pattern, and those with allergic asthma, minor threshold dose, or higher egg sIgE (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text